Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NXP004
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NXP004
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
NXP004 showed a dose-dependent reduction in the secretion of several key ECM components.These data suggest NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RXC006
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC006
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: $377.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2020
Details:
Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ILR201104
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ILR201104
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: DynPort
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 06, 2020
Details:
The Immune Regulation entered into a Teaming Agreement with DynPort Vaccine Company LLC to jointly evaluate the potential of Immune Regulation’s drug product ILR201104 to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS) in US clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RXC007
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020
Details:
Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
